Skip to main content

Table 1 Characteristics and treatments of patients receiving rituximab

From: The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease

Baseline Characteristics (N = 177)
Age (years) at first rituximab 47 (13–82)
Male sex 54 (31%)
Diagnosis 100 (56%)
  Primary Systemic Vasculitis 75 (42%)
  Granulomatosis with polyangiitis (Wegener’s) 15 (8%)
  Microscopic Polyangiitis 10 (6%)
  Churg Strauss Syndrome 43 (24%)
  Systemic lupus erythematosus 3 (2%)
  Behcet’s disease 3 (2%)
  Henoch Schonlein Purpura 28 (16%)
  Other#  
Prior disease duration (months) 52 (0–396)
Prior cyclophosphamide (N = 176) 121 (69%)
Cumulative cyclophosphamide (g) (N = 171) 8 (0–163)
Prior therapies (N = 176)  
  Mycophenolate Mofetil 123 (70%)
  Azathioprine 107 (61%)
  Methotrexate 46 (26%)
  Intravenous immunoglobulin 40 (23%)
  Hydroxychloroquine 29 (16%)
  Anti-tumor necrosis factors agents 26 (15%)
  Plasma exchange 26 (15%)
  Alemtuzumab 20 (11%)
  Other IS/IM$ 63 (36%)
Number of prior IS/IM agents (excluding steroids) (N = 176) 3 (0–14)
Patient characteristics at first rituximab infusion
Indication  
  Active disease 127 (72%)
  Consolidation of remission 50 (28%)
Relapsing/refractory disease 170 (96%)
New disease 7 (4%)
Follow-up (months) 43 (2–100)
Cyclophosphamide at time of rituximab 42 (24%)
Rituximab total dose  
  Total dose (g) (N = 177) 6 (1–20.2)
  Dose/BSA (g/m2) (N = 149) 3.3 (0.8-10.4)
  Dose/BSA/year (g/m2/year) (N = 149) 1.1 (0.1-3.2)
  1. Data are presented for 177 patients, unless otherwise stated. Results are expressed as either medians and ranges or numbers and proportions. All values reported at/from the time of first ever rituximab.
  2. #other diagnoses include neurological autoimmune disease (N = 7), cryoglobulinaemia (N = 3), urticarial vasculitis (N = 3), polyarteritis nodosa (N = 2), polychondritis (N = 2), polymyositis (N = 2), Takayasu’s disease (N = 1), membranous nephropathy (N = 1), bullous pemphigoid (N = 1) and unclassified autoimmune disease (N = 6).
  3. $other IS/IM (immunosuppressant/immunomodulatory) agents include: ciclosporin (N = 15), gusperimus (N = 13), tacrolimus (N = 10), dapsone (N = 4), leflunomide (N = 4), sirolimus (N = 3), antithymocyte globulin (N = 2), colchicine (N = 2), gold (N = 2), abatacept (N = 1), mefloquine (N = 1), other (N = 6).
  4. BSA – body surface area.